Journal Mobile Options
Table of Contents
Vol. 65, Suppl. 2, 2003
Issue release date: November 2003
Section title: Paper
Oncology 2003;65(suppl 2):80–84
(DOI:10.1159/000073366)

Ifosfamide in the Adjuvant Therapy of Soft Tissue Sarcomas

Frustaci S. · De Paoli A. · Bidoli E. · La Mura N. · Berretta M. · Buonadonna A. · Boz G. · Gherlinzoni F.
Departments of aMedical Oncology, bRadiation Oncology and cEpidemiology and Biostatistics, Centro di Riferimento Oncologico di Aviano and dDivision of Orthopedics, General Hospital, Gorizia,Italy

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 11/4/2003

Number of Print Pages: 5
Number of Figures: 4
Number of Tables: 1

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL

Abstract

Ifosfamide and anthracyclines are the only active agents in advanced soft tissue sarcomas. Doxorubicin was always used in sarcomas, whereas ifosfamide was reintroduced in the clinic after the discovery of mesna which prevents its typical dose-limiting toxicity: hemorrhagic cystitis. In the adjuvant setting, doxorubicin was used alone or in combination in the first-generation trials, whereas its parent compounds epirubicin and ifosfamide were employed in the second-generation adjuvant trials, which started in the early 90s. Other relevant aspects of the second-generation trials are the use of the hematopoietic growth factors and the increase of the dose intensity, the introduction of more restrictive selection criteria and the use of the two most active agents, ifosfamide and anthracyclines. Only the Italian cooperative trial has been concluded, and the results reported and updated. After a median follow-up of 89.6 months (range 56–119), the intention-to-treat analysis still reveals a difference in overall survival which, however, is not statistically significant. However, the 5-year overall survival estimate, which is a reasonable end point for the survival analysis of adjuvant treatment in soft tissue sarcomas, was 66.0 and 46.1% for the treatment and the control groups, respectively (p = 0.04).


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 11/4/2003

Number of Print Pages: 5
Number of Figures: 4
Number of Tables: 1

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Enziger FM, Weiss SW: General considerations; in Enziger FM, Weiss SW (eds): Soft Tissue Tumors. St Louis, Mosby, 1988, pp 1–18.
  2. Zahm SH, Fraumeni JF Jr: The epidemiology of soft tissue sarcomas. Semin Oncol 1997;24:504–514.
  3. Guillou L, Coindre JM, Bonichon F et al: Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350–362.
  4. Suit HD: Tumors of the connective and supporting tissues. Regaud Lecture, Granada 1994. Radiother Oncol 1995;34:93–104.
  5. Spiro IJ, Gebhardt MC, Candace Jennings L, Mankin HJ, Harmon DC, Suit HD: Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery. Semin Oncol 1997;24:540–546.
  6. Elias AD: Future directions in the management of soft tissue sarcomas. Hematol Oncol 1992;10:53–60.
  7. Mazanet R, Antman KH: Sarcomas of soft tissue and bone. Cancer 1991;68:463–473.
  8. Elias AD: Chemotherapy for soft tissue sarcomas. Clin Orthop 1993;289:94–105.
  9. Weiss RB: The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol 1992;19:670–686.
  10. Mourisden HT, Bastholt L, Somers R et al: Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 1987;23:1477–1483.
  11. Elias AD, Eder JP, Shea T et al: High-dose ifosfamide with mesna uroprotection: A phase I study. J Clin Oncol 1990;8:170–178.
  12. Antman KH, Elias AD: Dana-Farber Cancer Center Institute studies in advanced sarcoma. Semin Oncol 1990;17(suppl 2):7–15.
  13. Sarcoma Metanalysis Collaboration: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma: Meta-analysis of individual data. Lancet 1997;350:1647–1654.
  14. Frustaci S, Gherlinzoni F, De Paoli A, Pignatti G, Zmerly H, Azzarelli A et al: Preliminary results of an adjuvant randomized trial on high risk extremity soft tissue sarcomas. The interim analysis. Proc Am Soc Clin Oncol 1997;16:496, abstr 1785.
  15. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238–1247.
  16. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial. J Clin Oncol, Classic Paper and Currents Comments; Highlights of Sarcoma Research 2002;7:868–877.